MAIA Biotechnology Provides A Patient Enrollment Update For Its Ongoing Pivotal Phase 3 Trial, THIO-104; 29 Patients Have Been Dosed Among 34 Activated Trial Sites In 6 Foreign Countries

뉴스 본문을 불러오고 있어요.

MAIA Biotechnology Provides A Patient Enrollment Update For Its Ongoing Pivotal Phase 3 Trial, THIO-104; 29 Patients Have Been Dosed Among 34 Activated Trial Sites In 6 Foreign Countries | 웨이프 WAPE

MAIA Biotechnology Provides A Patient Enrollment Update For Its Ongoing Pivotal Phase 3 Trial, THIO-104; 29 Patients Have Been Dosed Among 34 Activated Trial Sites In 6 Foreign Countries

기사 요약

관련 종목

댓글 —